HALEOSLABSHALEOS LABS LIMITED
Pharma · Biotechnology · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also exports its products. The company was formerly known as SMS Lifesciences India Limited and changed its name to Haleos Labs Limited in August 2025. Haleos Labs Limited was founded in 1990 and is based in Hyderabad, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on HALEOSLABS — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Debt/Equity: 0.48
- • Promoter holding: 75.0%
- • Valuation vs sector: P/E 27.9 vs sector 40.5
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • Supertrend: bullish
Bull case
- • Debt/Equity: 0.48
- • Promoter holding: 75.0%
- • Valuation vs sector: P/E 27.9 vs sector 40.5
- • Price vs SMA200: above
Bear case
- • Revenue growth: -11.6% YoY
- • Profit growth: -36.4% YoY
- • MACD: bearish
- • Price vs EMA21: below
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Weak fundamentals — technical strength may not sustain
- • Revenue growth: -11.6% YoY
- • Profit growth: -36.4% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹57.55). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.